Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06533527 · ClinicalTrials.gov registry record · Phase 4
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
A Phase 4 study of Obesity and Diabetes Mellitus, Type 2, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 69
- Enrollment target
- 2
- Study locations
NCT06533527: Completed Phase 4 study of Obesity and Diabetes Mellitus, Type 2, sponsored by The Cleveland Clinic.
NCT06533527 is a Phase 4 study of Obesity and Diabetes Mellitus, Type 2 that has completed, run by The Cleveland Clinic. The registered enrollment target is 69 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06533527, a Phase 4 study of Obesity and Diabetes Mellitus, Type 2, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 69 participants
- Enrollment target
- 2
- Study locations
Study Summary
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV). Primary Outcomes: * Residual gastric volume that precludes adequate endoscopic examination * Residual gastric volume that necessitates premature termination of the endoscopy procedure * Need for endotracheal intubation due to stomach contents. * Occurrence of aspiration events requiring extended observation/monitoring, unplanned therapeutics, and/or hospital admission Secondary Outcomes: * Presence of any solid food * Presence of moderate liquid content * Increased RGV(Residual Gastric Volume) defined as any amount of solid content or \> 0.8 mL/Kg of fluid content (measured from the aspiration/suction canister). * Differences in primary and secondary outcomes between different medications
Primary Outcome
Residual gastric volume (RGV) that precludes adequate endoscopic examination
Conditions Studied
Interventions
- DRUG GLP-1 medication
Study Locations (2)
Florida
- Cleveland Clinic - Weston
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2025-05-20 |
| Phase | Phase 4 |
What the finished NCT06533527 record still lists
NCT06533527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (92% lower).
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which GLP-1 medication is the first listed.
NCT06533527 reports a single indexed study location in Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT06533527 about?
NCT06533527 is a clinical study titled "Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy". To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV). Primary Outcomes: * Residual gastric volume that precludes adequate endoscopic examination * Residual gastric volume that necessitates premature terminatio...
What is the current status of trial NCT06533527?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 69 participants. The study started on 2024-07-31. Estimated completion is 2025-05-20.
What conditions does trial NCT06533527 study?
This clinical trial studies the following conditions: Obesity, Diabetes Mellitus, Type 2, Gastroparesis.
What interventions are being tested in trial NCT06533527?
The interventions under investigation include: GLP-1 medication (DRUG).
Who is sponsoring clinical trial NCT06533527?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06533527 being conducted?
This trial has 2 study locations across Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06533527's enrollment target sits among peer trials
69 606th of 1053 higher than 444 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI